Real‐world treatment and prognostic factors for survival in <scp>ALK</scp> + non‐small cell lung cancer ( <scp>NSCLC</scp> ) patients with brain metastases in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world treatment and prognostic factors for survival in ALK + non‐small cell lung cancer ( NSCLC ) patients with brain metastases in China

Published:2022-11-21 Issue:3 Volume:14 Page:237-245
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Li Na¹²^ORCID,Xie Mingying²³^ORCID,Zhou Zichao²³^ORCID,Sheng Jiamin²^ORCID,Yu Xiaoqing²^ORCID,Fan Yun²^ORCID

Affiliation:

1. The First Clinical Medical College of Wenzhou Medical University Wenzhou China

2. Department of Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences Hangzhou China

3. The Second Clinical Medical College of Zhejiang Chinese Medical University Hangzhou China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14739

Reference41 articles.

1. Genetic alterations defining NSCLC subtypes and their therapeutic implications

2. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene

3. PROFILE 1014: lessons for the new era of lung cancer clinical research;Noonan SA;Transl Lung Cancer Res,2015

4. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer

5. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP